Announcement PDF Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Imagion Biosystems Limited ABN 42 616 305 027 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Robert Romeo Proulx Date of last notice 8 May 2026 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Direct Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. N/A Date of change 25 June 2026 Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 No. of securities held prior to change 1. 4,470,749 Ordinary Shares 2. 50,000 Unlisted Performance Options, exercisable at $1.12, vesting on 1 May 2022, expiring 1 May 2027. 3. 50,000 Unlisted Performance Options, exercisable at $1.12, vesting on 1 May 2023, expiring 1 May 2028. 4. 600,000 Unlisted Class A Performance Rights (expiring 22 August 2028), vesting if the company’s share price is at least $0.10 (10 cents) over 20 consecutive trading days. 5. 625,000 Options, exercisable at $0.04 (4 cents), expiring 13 December 2027. 6. 2,000,000 Unlisted Options, exercisable at $0.012 (1.2 cents), expiring 29 May 2030, comprising of: (a) 400,000 Options vesting on submission of MagSense@ HER2 IND for Phase 2 study (or equivalent regulatory submission for another jurisdiction); (b) 400,000 Options vesting on first patient dosed in a Phase 2 study; (c) 1,000,000 Options vesting on completion of a Phase 2 study; and (d) 200,000 Options vesting on submission of an IND (or like regulatory approval) for a second imaging agent. 7. 1,666,667 Listed Options, exercisable at $0.04 (4 cents), expiring 13 December 2027. Class Unlisted Class D Performance Rights Unlisted Class E Performance Rights Number acquired 3,000,000 Performance Rights comprising of: (a) 1,000,000 Unlisted Class D Performance Rights (b) 2,000,000 Unlisted Class E Performance Rights Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3 Number disposed N/A Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation Nil Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. Appendix 3Y Page 4 01/01/2011 No. of securities held after change 1. 4,470,749 Ordinary Shares 2. 50,000 Unlisted Performance Options, exercisable at $1.12, vesting on 1 May 2022, expiring 1 May 2027. 3. 50,000 Unlisted Performance Options, exercisable at $1.12, vesting on 1 May 2023, expiring 1 May 2028. 4. 600,000 Unlisted Class A Performance Rights (expiring 22 August 2028), vesting if the company’s share price is at least $0.10 (10 cents) over 20 consecutive trading days. 5. 625,000 Options, exercisable at $0.04 (4 cents), expiring 13 December 2027. 6. 2,000,000 Unlisted Options, exercisable at $0.012 (1.2 cents), expiring 29 May 2030, comprising of: (a) 400,000 Options vesting on submission of MagSense@ HER2 IND for Phase 2 study (or equivalent regulatory submission for another jurisdiction); (b) 400,000 Options vesting on first patient dosed in a Phase 2 study; (c) 1,000,000 Options vesting on completion of a Phase 2 study; and (d) 200,000 Options vesting on submission of an IND (or like regulatory approval) for a second imaging agent. 7. 1,666,667 Listed Options, exercisable at $0.04 (4 cents), expiring 13 December 2027. 8. 3,000,000 Performance Rights comprising of: (a) 1,000,000 Unlisted Class D Performance (expiring 24 June 2030), vesting if the company achieves a market capitalisation of $20m and maintains this for 20 consecutive trading days. (b) 2,000,000 Unlisted Class E Performance (expiring 24 June 2030), vesting if the company achieves a market capitalisation of $30m and maintains this for 20 consecutive trading days. Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 5 Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Grant of Performance Rights as approved at the Annual General Meeting held on 26 May 2026. Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed N/A Interest acquired N/A Interest disposed N/A Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation N/A Interest after change N/A Part 3 – +Closed period Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? N/A If so, was prior written clearance provided to allow the trade to proceed during this period? N/A If prior written clearance was provided, on what date was this provided? N/A Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 General Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Imagion Biosystems Limited ABN 42 616 305 027 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Brett Mitchell Date of last notice 30 September 2025 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Indirect Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. 1. Mr Brett Mitchell and Mrs Michelle Mitchell <Lefthanders Super Fund A/C> (Trustee and Beneficiary) 2. Mr Brett Mitchell and Mrs Michelle Mitchell <Mitchell Spring Family A/C> (Trustee and Beneficiary) Date of change 25 June 2026 Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 General No. of securities held prior to change 1. 5,937,575 Ordinary Shares 2. 625,000 Unlisted Performance Rights (expiring 22 August 2028), comprising of: (a) 187,500 Class A (Share price of at least $0.10 (10 cents) over 20 consecutive trading days); (b) 187,500 Class B (Market capitalisation of at least $7.5 million over 20 consecutive trading days); and (c) 250, 000 Class C (Market capitalisation of at least $12.5 million over 20 consecutive trading days). 3. 625,000 Unlisted Performance Rights (expiring 22 August 2028), comprising of: (a) 187,500 Class A (Share price of at least $0.10 (10 cents) over 20 consecutive trading days); (b) 187,500 Class B (Market capitalisation of at least $7.5 million over 20 consecutive trading days); and (c) 250, 000 Class C (Market capitalisation of at least $12.5 million over 20 consecutive trading days). 4. 1,875,000 Director Placement Options, exercisable at $0.04, expiring 13 December 2027. 5. 2,000,000 Unlisted Options, exercisable at $0.019 (1.9 cents), expiring 29 May 2028, comprising of: (a) 666,667 Options vesting on the issue date; (b) 666,667 Options vesting one year from the issue date; and (c) 666,666 Options vesting on the second anniversary of the issue date. 6. 1,666,667 Listed Options, exercisable at $0.04 (4 cents), expiring 13 December 2027. Class (a) Unlisted Class D Performance Rights (b) Unlisted Class E Performance Rights Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3 General Number acquired 1,600,000 Performance Rights comprising of: (a) 600,000 Unlisted Class D Performance (b) 1,000,000 Unlisted Class E Performance Number disposed N/A Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation N/A Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. Appendix 3Y Page 4 01/01/2011 General No. of securities held after change 1. 5,937,575 Ordinary Shares 2. 625,000 Unlisted Performance Rights (expiring 22 August 2028), comprising of: (a) 187,500 Class A (Share price of at least $0.10 (10 cents) over 20 consecutive trading days); (b) 187,500 Class B (Market capitalisation of at least $7.5 million over 20 consecutive trading days); and (c) 250, 000 Class C (Market capitalisation of at least $12.5 million over 20 consecutive trading days). 3. 625,000 Unlisted Performance Rights (expiring 22 August 2028), comprising of: (a) 187,500 Class A (Share price of at least $0.10 (10 cents) over 20 consecutive trading days); (b) 187,500 Class B (Market capitalisation of at least $7.5 million over 20 consecutive trading days); and (c) 250, 000 Class C (Market capitalisation of at least $12.5 million over 20 consecutive trading days). 4. 1,875,000 Director Placement Options, exercisable at $0.04, expiring 13 December 2027. 5. 2,000,000 Unlisted Options, exercisable at $0.019 (1.9 cents), expiring 29 May 2028, comprising of: (a) 666,667 Options vesting on the issue date; (b) 666,667 Options vesting one year from the issue date; and (c) 666,666 Options vesting on the second anniversary of the issue date. 6. 1,666,667 Listed Options, exercisable at $0.04 (4 cents), expiring 13 December 2027. 7. 1,600,000 Performance Rights comprising of: (a) 600,000 Unlisted Class D Performance (expiring 24 June 2030), vesting if the company achieves a market capitalisation of $20m and maintains this for 20 consecutive trading days. (b) 1,000,000 Unlisted Class E Performance (expiring 24 June 2030), vesting if the company achieves a market capitalisation of $30m and maintains this for 20 consecutive trading days. Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 5 General Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back Grant of Performance Rights as approved at the Annual General Meeting held on 26 May 2026. Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed N/A Interest acquired N/A Interest disposed N/A Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation N/A Interest after change N/A Part 3 – +Closed period Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? N/A If so, was prior written clearance provided to allow the trade to proceed during this period? N/A If prior written clearance was provided, on what date was this provided? N/A Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Imagion Biosystems Limited ABN 42 616 305 027 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Dr Nina Webster Date of last notice 17 September 2025 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Indirect Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. JACLANI Pty Ltd <JACLANI FAMILY A/C> Date of change 25 June 2026 No. of securities held prior to change 565,211 Fully Paid Ordinary Shares Class (a) Unlisted Class D Performance Rights (b) Unlisted Class E Performance Rights Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Number acquired 1,600,000 Performance Rights comprising of: (a) 600,000 Unlisted Class D Performance (b) 1,000,000 Unlisted Class E Performance Number disposed N/A Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation N/A No. of securities held after change 1. 565,211 Ordinary Shares 2. 1,600,000 Performance Rights comprising of: (c) 600,000 Unlisted Class D Performance (expiring 24 June 2030), vesting if the company achieves a market capitalisation of $20m and maintains this for 20 consecutive trading days. (d) 1,000,000 Unlisted Class E Performance (expiring 24 June 2030), vesting if the company achieves a market capitalisation of $30m and maintains this for 20 consecutive trading days. Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back Grant of Performance Rights as approved at the Annual General Meeting held on 26 May 2026. Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3 Date of change N/A No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed N/A Interest acquired N/A Interest disposed N/A Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation N/A Interest after change N/A Part 3 – +Closed period Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? N/A If so, was prior written clearance provided to allow the trade to proceed during this period? N/A If prior written clearance was provided, on what date was this provided? N/A